Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,026
archived clinical trials in
Epilepsy

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
278
mi
from 43215
Charlottesville, VA
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
278
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated:  12/31/1969
Investigator Site 102
mi
from 43215
Brno,
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated: 12/31/1969
Investigator Site 102
mi
from 43215
Brno,
Click here to add this to my saved trials
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
624
mi
from 43215
Minneapolis, MN
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1993
mi
from 43215
Fresno, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1993
mi
from 43215
Fresno, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2017
mi
from 43215
Oxnard, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2017
mi
from 43215
Oxnard, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
862
mi
from 43215
Bradenton, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
862
mi
from 43215
Bradenton, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
747
mi
from 43215
Ocala, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
747
mi
from 43215
Ocala, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
693
mi
from 43215
Panama City, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
693
mi
from 43215
Panama City, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
933
mi
from 43215
Wellington, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
933
mi
from 43215
Wellington, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
188
mi
from 43215
Louisville, KY
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
776
mi
from 43215
Hammond, LA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
776
mi
from 43215
Hammond, LA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
340
mi
from 43215
Waldorf, MD
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
340
mi
from 43215
Waldorf, MD
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
630
mi
from 43215
Golden Valley, MN
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
630
mi
from 43215
Golden Valley, MN
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
585
mi
from 43215
Springfield, MO
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
585
mi
from 43215
Springfield, MO
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1612
mi
from 43215
Missoula, MT
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1612
mi
from 43215
Missoula, MT
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
418
mi
from 43215
Camden, NJ
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
418
mi
from 43215
Camden, NJ
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
321
mi
from 43215
Greensboro, NC
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
321
mi
from 43215
Greensboro, NC
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
103
mi
from 43215
Canton, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
103
mi
from 43215
Canton, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
6
mi
from 43215
Columbus, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
64
mi
from 43215
Dayton, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
64
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1130
mi
from 43215
Lubbock, TX
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1130
mi
from 43215
Lubbock, TX
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
394
mi
from 43215
Madison, WI
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1959
mi
from 43215
Orange, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
897
mi
from 43215
Port Charlotte, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
897
mi
from 43215
Port Charlotte, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
110
mi
from 43215
Akron, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
110
mi
from 43215
Akron, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
104
9156
mi
from 43215
Chatswood,
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
104
9156
mi
from 43215
Chatswood,
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
351
mi
from 43215
Durham, NC
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
351
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1064
mi
from 43215
Austin, TX
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1064
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1983
mi
from 43215
Los Angeles, CA
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1983
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
703
mi
from 43215
Gulf Breeze, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
703
mi
from 43215
Gulf Breeze, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
898
mi
from 43215
Port Charlotte, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
898
mi
from 43215
Port Charlotte, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
934
mi
from 43215
Wellington, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
934
mi
from 43215
Wellington, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
617
mi
from 43215
Saint Paul, MN
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
501
mi
from 43215
Memphis, TN
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
501
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Buspirone Therapy for Localized Epilepsy
A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Buspirone Therapy for Localized Epilepsy
A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
154
mi
from 43215
Lexington, KY
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
110
mi
from 43215
Akron, OH
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
110
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
622
mi
from 43215
Little Rock, AR
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials